Leading Cell Therapy Developer to Attend BIO in Boston, June 5-8
HOUSTON (June 5, 2023) — CTMC, a joint venture between MD Anderson Cancer Center and
Resilience, celebrates one year since its founding to accelerate life-saving cell therapies
reaching patients. During its first year, CTMC has partnered with MD Anderson investigators
and biotech companies to bring several novel cell therapies through Investigational New Drug
(IND)-enabling studies and U.S. Food and Drug Administration (FDA) interactions to initiate
clinical development.
Access the full press release: CTMC 1st Anniversary